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Abstract Extensively hydrolyzed (EH) formula with
Lactobacillus rhamnosus GG (LGG) was demonstrated to
alleviate cow’s milk allergy (CMA) symptoms and promote
faster acquisition of tolerance to cow’s milk protein. We pre-
viously demonstrated that partially hydrolyzed (PH) and EH
formulas with LGG supported normal growth in healthy-term
infants through 120 days of age. The objective of the current
study was to evaluate growth, development, and specific ad-
verse events through 5 years of age in participants from that
cohort who continued receiving study formula. Infants who
completed a double-blind, randomized growth and tolerance
study were eligible to continue receiving the assigned study
formula through 1 year of age (control: EH casein formula,
EHF, or one of two investigational formulas: EH casein for-
mula with LGG (EHF-LGG) or a PH formula with LGG
(PHF-LGG)) and participate in follow-up through 5 years of
age. Anthropometric measures, behavior development, and
specific adverse events were recorded. No significant
differences in achieved weight and height or behavioral devel-
opment outcomes at 3 or 5 years of age were observed among
study groups. Few statistically significant differences in the
incidence of specific infection-related events through years 3
or 5 were observed among study groups, none of which were
considered clinically relevant.
Conclusion: Extensively and partially hydrolyzed formulas
with LGG were associated with normal growth and develop-
ment and long-term safety through 5 years of age.
What is Known:
• Infants with cow’s milk allergy often experience allergic manifestations
that can lead to poor nutrition status and poor growth.
• Providing partially hydrolyzed (PH) and EH formulas with or without
LGG in infants can support normal growth in healthy-term infants.
What is New:
• This study provides long-term safety data for the first 5 years of life on
the use of extensively and partially hydrolyzed formulas with LGGwhen
fed through 1 year of age.
• Extensively and partially hydrolyzed formulas with LGG are associated
with normal growth, development, and long-term safety through 5 years
of age.
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Introduction
Cow’s milk allergy (CMA) affects ∼3% of infants [1, 2] who
have immediate (IgE-mediated) or delayed onset (non-IgE-
mediated) reactions to cow’s milk protein (CMP), commonly
manifested as atopic dermatitis (AD), urticaria, wheezing/
asthma, allergic rhinitis, or diarrhea [1, 3]. The majority of
infants and children with CMA have two or more symptoms
that significantly impact quality of life [4]. Although 80% of
children affected can tolerate intact CMP by 3 years of age, it
may take up to 5 years or longer for those with IgE-mediated
reactions to achieve tolerance [3]. In addition, these children
are at higher risk of subsequent development of allergy to
other foods and/or inhalants [5–7]. The current management
of CMA is based on complete avoidance of intact CMP [1, 3].
Extensively hydrolyzed (EH) cow’s milk-based formulas with
demonstrated reduced allergenicity are recommended for in-
fants with CMA [8–10]. Efficacy to manage infants and chil-
dren with CMA has been demonstrated for EH casein formula
[11–13]. There are many risk factors for poor growth in chil-
dren with CMA, including the impact of the allergic manifes-
tations on nutritional status, gut inflammation causing im-
paired nutrient absorption, and restricted diet [14]. For exam-
ple, more children with CMA consume dietary calcium below
the recommendations compared with children without CMA
[15]. Moreover, use of a hydrolyzed whey formula was asso-
ciated with slower weight and length growth in infants with
CMA (compared to an amino acid-based formula) [16].
Therefore, assessment of growth and development with EH
formulas is a critical safety parameter, especially when a pro-
biotic is added to the formula, since there is limited data on
growth with probiotic-supplemented formulas [17].
Probiotics are livemicroorganisms that, when administered
in adequate amounts, have been shown in properly controlled
studies to confer a health benefit on the host [18].Mechanisms
of action include transitory colonization of the intestinal tract
[19, 20], increase of anti-inflammatory cytokines, and stabili-
zation of tight junctions in the gut [21]. Recent data suggest
that Lactobacillus rhamnosus GG (LGG), the most studied
probiotic, may not only impact the host intestinal mucosa
directly through adhesion and immunomodulatory interac-
tions [22] but also stimulate anti-inflammatory pathways and
butyrate production in the gut resident bacteria [19, 23].
Recent meta-analyses concluded that probiotics, notably
Lactobacillus, reduce risk of antibiotic-associated diarrhea
[24] and may decrease incidence of acute respiratory infec-
tions [25, 26]. Furthermore, current ESPGHAN guidelines
recommend the use of LGG in children at risk of antibiotic-
associated diarrhea [27]. Specific probiotics, especially LGG,
may also play a role in preventing or managing atopic eczema
[28, 29]. Infants with CMA who received EH formula with
LGG demonstrated improved gut barrier function and experi-
enced a faster acquisition of tolerance to CMP [23, 28,
30–32]. Although safety issues associated with the use of live
probiotic bacteria are rare and have been reported only in
immunocompromised or seriously ill individuals, there are
still safety concerns associated with the use of live probiotic
bacteria [33, 34].
Consequently, continued evaluation of hydrolyzed formu-
las with LGG for infant growth and development, as well as
long-term safety after early-life usage, is warranted. We pre-
viously demonstrated that partially hydrolyzed (PH) and EH
formulas with or without LGG support normal growth in a
cohort of healthy-term infants with no differences in formula
tolerance and immune markers through 120 days of age [35].
In the current study, we evaluated growth and development,
specific allergic and infectious events, and serious adverse
events through 5 years of age in participants from that cohort
who continued receiving study formulas through 1 year of
age.
Methods
Participants were originally recruited for a double-blind,
controlled, parallel group, prospective, multicenter study
that evaluated growth from 14 to 120 days of age as the
primary objective in infants randomly assigned to receive:
control EH casein formula (EHF; Nutramigen LIPIL,
Mead Johnson Nutrition, Evansville, IN) or one of two
investigational formulas containing LGG (106 CFU/g
powder; ATCC 53103, Valio, Ltd.): EH casein formula
with LGG (EHF-LGG) or a PH whey/casein (60:40) for-
mula with LGG (PHF-LGG) [35].
Current study
Participants who completed the previous study [35] were eli-
gible to enroll in the current study and continue with the
assigned randomization number and assigned study formula
through 365 days (1 year) of age. Anthropometric measures
(body weight and height) were recorded, and behavioral de-
velopment was assessed using selected age-appropriate mile-
stones (adapted from [36]) through the study period (Table 1).
All adverse events documented in the medical charts and those
reported by the parent were recorded through 1 year of age.
After 1 year of age, specific adverse events (allergy- and in-
fection-related) and all serious adverse events were recorded.
Parents or guardians provided written informed consent
prior to enrollment. The research protocol and informed con-
sent forms observing the Declaration of Helsinki (including
October 1996 amendment) were approved by the institutional
review board/ethics committee of each participating institu-
tion. The study complied with good clinical practices.
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Statistical analysis
Mean weight and height were analyzed by ANOVA. The pro-
portion of participants in each study group who met all behav-
ioral development milestones was compared using Fisher’s
exact test. The proportion of participants in each group who
experienced a specific adverse event at least one time was
analyzed using Fisher’s exact test. These analyses included
events occurring through 3 years of age (year 3, based on all
participants with adverse event data during the second and/or
third year of life) and through 5 years of age (year 5, based on
all participants with adverse event data during the fourth year
of life). All P values reported were based on two-tailed tests
and considered statistically significant if <0.05. All analyses
were performed using SAS version 9 (SAS Institute, Cary,
North Carolina).
Results
In the original study cohort, a total of 289 participants (EHF,
95; EHF-LGG, 95; PHF-LGG, 99) were randomized to study
formula feeding groups [35]. A total of 183 participants (EHF,
63; EHF-LGG, 53; PHF-LGG, 67) were enrolled in the cur-
rent study. Birth anthropometric measures (weight, length, and
head circumference) and participant demographics, including
smoking at home at 14 days of age and family history of
allergy (data not shown), were similar among study groups.
No significant differences were detected for achieved weight
and height at 3 or 5 years of age (Table 2). Over 80% of infants
met all of the selected milestones of behavioral development,
and no group differences in milestones were detected at 3 or
5 years of age.
No significant differences in study discontinuation rates
were detected with a total of 101 participants (EHF, 32;
EHF-LGG, 32; PHF-LGG, 37) completing the follow-up
through 5 years of age. No significant differences among
groups were observed for specific allergy-related adverse
events through years 3 or 5 (Table 3). The incidence of ton-
sillitis in the EHF-LGG compared to the PHF-LGG group and
the incidence of viral skin infections in the EHF-LGG com-
pared to the EHF group were significantly higher through year
3 (Table 4). With the exception of a significantly higher inci-
dence of tonsillitis in the EHF-LGG compared to the PHF-
LGG group, no significant differences were observed in the
incidence of specific infection-related adverse events through
year 5 (Table 4). No serious adverse events correlated to con-
sumption of LGG were reported in the EH-LGG or PH-LGG
group through year 5.
Discussion
This study demonstrated safety for growth, development, and
health events during a prolonged period of time (5 years) in
children who received investigational EH and PH formulas
with LGG through 1 year of age. We previously demonstrated
that the investigational formulas with LGG were well tolerat-
ed and promoted adequate growth in infants from 14 through
120 days of age [35]. In the current study, both investigational
formulas with LGG were associated with normal growth and
development through 5 years of age, as well as absence of
relevant infections or allergic events, or serious adverse events
that could be attributed to early consumption of LGG.
Table 2 Growth outcomes through 5 years of agea
Time point Study group Weight (kg) Height (cm)
3 years EHF (n = 37) 14.8 ± 0.3 95.5 ± 0.6
EHF-LGG (n = 31) 15.5 ± 0.3 96.6 ± 0.7
PHF-LGG (n = 41) 15.3 ± 0.3 96.9 ± 0.6
5 years EHF (n = 28) 19.4 ± 0.5 110.5 ± 0.9
EHF-LGG (n = 32) 20.8 ± 0.5 111.6 ± 0.8
PHF-LGG (n = 36) 20.1 ± 0.5 111.9 ± 0.8




from 3 to 5 years of agea
Milestone 3 years 5 years
Motor ● Rides tricycle ● Skips
● Stands momentarily on one foot
Language ● Knows age and sex ● Names four colors
● Counts three objects correctly ● Counts ten pennies correctly
● Repeats three numbers or sentence of six syllables ● Repeats sentence of ten syllables
Social ● Plays simple ball games (in Bparallel^
with other children)
● Dresses and undresses
● Helps undressing (unbuttons clothing
and puts on shoes)
●Asks questions about meanings of words
●Washes hands ● Domestic role-playing
a Adapted from [2]
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CMA and associated allergic manifestations may increase
energy requirements through skin, gastrointestinal or
respiratory inflammation, disrupted sleep patterns, and re-
duced absorption of major nutrients [37]. Assessment of
Table 3 Incidence of allergy-related adverse events through years 3 and 5a
Year 3 Year 5
Event, n (%) EHF (n = 52) EHF-LGG (n = 46) PHF-LGG (n = 57) EHF (n = 32) EHF-LGG (n = 36) PHF-LGG (n = 32)
Allergic rhinitisb 2 (4) 0 (0) 5 (9) 3 (9) 5 (16) 3 (8)
Allergic conjunctivitis 0 (0) 2 (4) 1 (2) 0 (0) 2 (6) 1 (3)
Allergic rhino-conjunctivitisb 0 (0) 0 (0) 0 (0) 1 (3) 0 (0) 0 (0)
Allergic sinusitisb 0 (0) 0 (0) 2 (4) 0 (0) 1 (3) 2 (6)
Wheezing 12 (23) 15 (33) 16 (28) 10 (31) 9 (28) 12 (33)
Reactive airway diseasec 1 (2) 2 (4) 1 (2) 6 (19) 4 (13) 5 (14)
Atopic dermatitis 16 (31) 19 (41) 20 (35) 11 (34) 16 (50) 14 (39)
Contact dermatitis 2 (4) 0 (0) 4 (7) 2 (6) 1 (3) 4 (11)
Urticaria 4 (8) 3 (7) 5 (9) 5 (16) 5 (16) 3 (8)
Food Allergy 0 (0) 3 (7) 3 (5) 1 (3) 2 (6) 3 (8)
Allergic Colitis 0 (0) 1 (2) 0 (0) 0 (0) 1 (3) 0 (0)
P < .05; data analyzed using Fisher’s exact test
a No significant differences among groups
b Reclassified as upper respiratory infection if diagnosed in children under 2 years of age
c Reclassified as wheezing if diagnosed in children under 2 years of age
Table 4 Incidence of infection-related adverse events through years 3 and 5
Year 3 Year 5
Event, n (%) EHF (n = 52) EHF-LGG (n = 46) PHF-LGG (n = 57) EHF (n = 32) EHF-LGG (n = 36) PHF-LGG (n = 32)
Acute gastroenteritis 23 (44) 24 (52) 27 (47) 21 (66) 19 (59) 22 (61)
Conjunctivitis 23 (44) 21 (46) 22 (39) 19 (59) 18 (56) 16 (44)
Rhinitis 5 (10) 5 (11) 7 (12) 4 (13) 7 (22) 5 (14)
Sinusitis 13 (25) 10 (22) 16 (28) 11 (34) 16 (50) 14 (39)
Tonsillitis 1 (2) 4 (9)a 0 (0) 0 (0) 5 (16)a 0 (0)
Pharyngitis 19 (37) 16 (35) 25 (44) 17 (53) 20 (63) 23 (64)
Laryngitis 9 (17) 9 (20) 7 (12) 6 (19) 8 (25) 6 (17)
Otitis media 44 (85) 37 (80) 47 (82) 28 (88) 27 (84) 33 (92)
Upper respiratory infection 51 (98) 45 (98) 56 (98) 31 (97) 32 (100) 36 (100)
Bronchiolitisc 2 (4) 0 (0) 0 (0) 2 (6) 0 (0) 2 (5)
Bronchitisd 1 (2) 4 (9) 3 (5) 1 (3) 6 (19) 7 (19)
Pneumonia 4 (8) 4 (9) 7 (12) 2 (6) 3 (9) 7 (19)
Lower respiratory infection 6 (12) 8 (17) 10 (18) 5 (16) 8 (25) 13 (36)
Bacterial skin infection 15 (29) 10 (22) 10 (18) 13 (41) 10 (31) 11 (31)
Viral skin infection 0 (0) 4 (9)b 1 (2) 0 (0) 3 (9) 1 (3)
Fungal skin infection 15 (29) 13 (28) 15 (26) 10 (31) 10 (31) 12 (33)
Sepsis 2 (4) 0 (0) 0 (0) 1 (3) 0 (0) 0 (0)
Data analyzed using Fisher’s exact text
a Significantly different, EHF-LGG versus PHF-LGG, P < .05
b Significantly different, EHF-LGG versus EHF, P < .05
c Reclassified as wheezing if diagnosed in children under 2 years of age
d Reclassified as upper respiratory infection if diagnosed in children under 2 years of age
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suitability of EH formula for growth in infants and children
with CMA can be challenging, given the impact of the allergic
condition on growth regardless of nutrient source. For exam-
ple, significantly lower mean weight-for-height has been re-
ported in children with atopic eczema compared to children
without atopic eczema in a follow-up study through 4 years of
age [14]. In healthy children with a family history of allergy
who received EH casein formula through 4 months of age,
slower BMI gain was reported in the first year of life but no
differences in BMI were detected by 6 years of age [38].
Likewise, results from the current study indicated that all par-
ticipants who received EH or PH formulas exhibited normal
growth (weight and height) by 5 years of age.
Infant formula with LGG has been available for many
years. This is the first study evaluating long-term growth
and safety of children fed formula with LGG through 1 year
of age. Perinatal administration of LGG through 6 months of
age to infants with a family history of allergy has been asso-
ciated with no health concerns and normal growth (height and
weight-for-height) [28]; it also restrained overweight, as indi-
cated by reduced birth weight-adjusted BMI at 4 years of age
[32]. A routine cow’s milk-based formula with LGG promot-
ed normal growth in healthy-term infants through 6 months of
age compared to formula without LGG [55]. In healthy-term
infants, we previously demonstrated that an EH casein formu-
la with LGG transiently colonized the intestinal tract and was
well tolerated and associated with normal growth through
120 days of age and with circulating fatty acids similar to
those of breastfed infants [40] [47]. Results of the current
study extend safety for growth and tolerance of EH and PH
formulas with LGG through 5 years of age in a healthy pop-
ulation and lead to the conclusion that early LGG supplemen-
tation is associated not only with normal infant growth but
also with healthy weight gain later in life.
The probiotic LGG has nearly 30 years of safe use. Risk
associated with LGG is considered low, though questions as-
sociated with live probiotic bacteria use, particularly in immu-
nocompromised and critically ill individuals, still arise [34,
39, 40]. LGG has demonstrated good safety profile in those
individuals, with no report of septicemia or other serious ad-
verse events [41–43]. In elderly people with declining im-
mune competence, dietary LGG was demonstrated to be safe
and well tolerated [44] and retrospective analyses of routine
LGG use in premature infants for a 6-year period in Italy [42]
and a 12-year period in Finland [43] demonstrated safety of
LGG. An isolated study reported an increased incidence of
wheezing in a group of high-risk infants who received perina-
tal supplementation with LGG compared to placebo, based on
physician diagnosis or parental report up to 2 years of age
[26]. In the current study, allergic and infectious adverse
events were compared among groups for a longer follow-up
period and no differences in wheezing were observed. We did
not observe an increase in any allergy-related events in the
groups receiving formulas supplemented with LGG. In fact,
one of the potential benefits of probiotic use is increased tol-
erance to various allergens via modulation of the gut immune
system and reinforcement of the intestinal mucosal barrier.
Infants with CMA developed an accelerated acquisition of
tolerance to cow’s milk after receiving EH formula with
LGG (compared to an EH formula without LGG) over a 12-
month period [30, 45]. LGG supplementation has also dem-
onstrated to decrease incidence of AD in high-risk population
[29]. In the present study, the incidence of AD through years 3
and 5 was not significantly different among study groups.
However, our population was not selectively comprised of
infants at high risk of allergy and had a smaller sample size,
both of which might explain the different outcomes.
Protection against gastrointestinal and respiratory infections is
among the potential benefits of probiotics and notably LGG [25,
46–48]. Such protection was not detected in our study, nor was a
deleterious effect of LGG. The incidence of tonsillitis through
years 3 and 5was higher in the EHF-LGG but not the PHF-LGG
group. Likewise, the incidence of viral skin infectionswas higher
in the EHF-LGG but not the PHF-LGG group through year 3,
with no significant differences through year 5. Therefore, the
differences were not consistently associated with the LGG-
enriched formulas and thus unlikely related to the presence of
LGG in the investigational formulas. In addition, the incidence
of tonsillitis in the EHF-LGG is within the incidence of tonsillitis
normally reported in this age group [49, 50]. Likewise, the inci-
dence of viral skin infections reported in the EHF-LGG group
through year 3 is within the expected incidence of these condi-
tions in young children [51, 52]. Consequently, in the current
healthy study population, the few significant differences ob-
served in the incidence of specific infection-related adverse
events are not considered clinically relevant.
Age-appropriate behavioral development is a valuable in-
dicator of long-term health and safety of early use of LGG.
Behavioral development may be influenced by multiple bio-
logical and environmental factors; however, age-appropriate
milestones assessing motor, language, and social skills can
appropriately evaluate development [36]. In the present study,
the great majority of infants met all developmental milestones
and no group differences were detected at 3 and 5 years of age,
demonstrating that study formulas supported normal behav-
ioral development through 5 years of age. Recent evidence
suggests that gut microbiota may impact neurocognitive out-
comes via the gut-brain-axis [47]. A study with preterm in-
fants demonstrated that early probiotic supplementation sig-
nificantly reduced infant crying and fussiness, indicating that
probiotic supplementation may reduce excessive crying and
irritability in infants [53]. A study in colicky term infants also
suggests that a combination of behavioral counseling, cow’s
milk elimination diet, and LGG supplementation may de-
crease the number of crying days [54]. Furthermore, a reduced
prevalence of attention-deficit hyperactivity disorder and
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Asperger syndrome at 13 years of age was observed in chil-
dren who received LGG through 6 months of age [55].
The use of LGG in EH formulas is a promising option due
to the potential of faster acquisition of tolerance to cow’s milk
protein in infants with CMA. Results of this study indicate that
extensively and partially hydrolyzed formulas with LGG,
when consumed by healthy-term infants through 1 year of
age, are associated with normal growth and development
and long-term safety through 5 years of age.
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